From 24/7 Wall St. · David Moadel · · 1m 20s
Moderna Jumps 9% After Melanoma Data Wins Prestigious Slot
Moderna stock surges 9% as Phase 3 melanoma trial data secures top presentation slot at major cancer conference
In brief
Moderna stock surges 9% as Phase 3 melanoma trial data secures top presentation slot at major cancer conference Market pricing the significance of a Presidential Symposium slot at a major oncology conference without new data Originally reported by 24/7 Wall St..
Presidential Symposium Slot
Moderna shares jumped 9% after its Phase 3 melanoma study earned a Presidential Symposium slot at the European Society for Medical Oncology conference in Madrid
“Moderna's Phase 3 adjuvant melanoma study for intismeran autogene was selected for a Presidential Symposium slot at the European Society for Medical Oncology congress”
Market Reaction
Moderna stock reached $167.90, up 9% while Merck rose 1% and BioNTech gained 2% on the news
What the Slot Means
The Presidential Symposium is the highest-profile presentation slot at the conference, reserved for data expected to change clinical practice
Why No New Data
The melanoma result was first reported in August, with today's announcement adding a fixed date and venue rather than new efficacy results
Merck and BioNTech Moves
Merck, the pembrolizumab partner, moved modestly while BioNTech gained on platform read-through without broader category impact
Next Data Window
Moderna will present the Phase 3 dataset on October 24 with an investor webcast, creating concentrated event risk
Market Pricing
The market is pricing the significance of the Presidential Symposium slot without new data, reflecting expectations of clinical impact
The one thing
Market pricing the significance of a Presidential Symposium slot at a major oncology conference without new data
